Update on prospective glaucoma intervention studies;Update prospektiver glaukomstudien

Klinische Monatsblatter fur Augenheilkunde

Volumn 222, Issue 10, 2005, Pages 807-813

  Arend, Kay Oliver ^a   Redbrake, C ^a  

^a Augenzentrum Alsdorf ^*  (Germany)

Author keywords

Glaucoma progression; Glaucoma therapy; Intervention studies; Normal tension glaucoma; Ocular hypertension; Open angle glaucoma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DORZOLAMIDE; PLACEBO;

BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE ACTIVITY; GLAUCOMA; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; PATIENT CARE; PERIMETRY; PROSPECTIVE STUDY; REVIEW; SCREENING; TRABECULECTOMY;

CLINICAL TRIALS; GLAUCOMA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; TREATMENT OUTCOME;

EID: 27844485558     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858210     Document Type: Review

References (14)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The Relationship Between Control of Intraocular Pressure and Visual Field Deterioration. Am J Ophthalmol 2000; 130: 429-440
2. Nouri-Mahdavi K et al. Prediktive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004; 111 (9): 1627-1635
3. Heijl A et al. Reduction of intraocular pressure and glaucoma progression. Results from the early manifest glaucoma trial. Arch Ophthalmol 2002; 120: 1268-1279
4. Katz J, Congdon N, Friedman DS. Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment. Arch Ophthalmol 1999; 117 (9): 1137-1142
5. Lichter P et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953
6. Collaborative normal-tension glaucoma study group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J of Ophthalmology 1998; 126 (4): 487-497
7. Leske MC et al. Early Manifest Glaucoma Trail. Design and Baseline Data. Ophthalmology 1999; 106: 2144-2153
8. Leske MC et al. Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol 2003; 121: 48-56
9. The European Glaucoma Prevention Study (EGPS) Group. The European Glaucoma Prevention Study Design and Baseline Description of the participants. Ophthalmology 2002; 109: 1612-1621
10. The European Glaucoma Prevention Study (EGPS) Group. Results of the european glaucoma prevention study. Ophthalmology 2005; 112: 366-375
11. Brandt JD et al. Central corneal thickness in the ocular hypertension treatment study (OHTS). Ophthalmology 2001; 108: 1779-1788
12. Gordon MO et al. The Ocular hypertension treatment study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-720
13. Lee BL, Wilson MR. Ocular hypertension treatment Study (OHTS) commentary. Curr Opin Ophthalmol 2003; (14): 74-77
14. Anderson DR et al. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol 2003; 136 (5): 820-829